• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

4'-Methylsulfanyl-biphenyl-3-carboxylic Acid (CAS No. 728918-92-1): A Comprehensive Overview

4'-Methylsulfanyl-biphenyl-3-carboxylic Acid, identified by the Chemical Abstracts Service Number (CAS No.) 728918-92-1, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This molecule, characterized by its biphenyl core structure modified with a methylsulfanyl group at the 4-position and a carboxylic acid moiety at the 3-position, has garnered attention due to its unique chemical properties and potential biological activities.

The biphenyl scaffold is a well-documented motif in medicinal chemistry, frequently employed in the design of drugs due to its structural stability and versatility in interacting with biological targets. The introduction of a methylsulfanyl group at the 4-position introduces a polar sulfur atom, which can enhance solubility and binding affinity to certain biological receptors. Additionally, the presence of a carboxylic acid group at the 3-position provides a site for further functionalization, enabling the synthesis of derivatives with tailored properties.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid and biological targets. Studies have shown that this compound exhibits promising binding affinity to various enzymes and receptors, suggesting its potential as an intermediate in the development of novel therapeutic agents. For instance, preliminary computational studies indicate that it may interact with enzymes involved in metabolic pathways, making it a candidate for further investigation in drug discovery.

The synthesis of 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid involves multi-step organic reactions, typically starting from commercially available biphenyl derivatives. The introduction of the methylsulfanyl group is achieved through nucleophilic substitution reactions, while the carboxylic acid functionality is introduced via oxidation or carboxylation techniques. These synthetic pathways have been optimized to ensure high yield and purity, making the compound accessible for both research and industrial applications.

In the realm of drug discovery, the unique structural features of 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid make it an attractive candidate for further exploration. Its biphenyl core provides a stable framework for interaction with biological targets, while the polar methylsulfanyl and carboxylic acid groups enhance binding affinity and solubility. Recent studies have highlighted its potential as an intermediate in the synthesis of kinase inhibitors, which are crucial in treating various cancers and inflammatory diseases.

The compound's potential applications extend beyond oncology. Research suggests that derivatives of 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid may exhibit antimicrobial properties, making them valuable in developing new antibiotics to combat resistant bacterial strains. Additionally, its structural motif is reminiscent of known anti-inflammatory agents, prompting investigations into its efficacy in modulating inflammatory responses.

The pharmacokinetic properties of 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid are also under scrutiny. Preliminary pharmacokinetic studies indicate that it exhibits moderate bioavailability and a reasonable half-life upon oral administration. These characteristics are favorable for drug development, as they suggest potential for once-daily dosing regimens. Furthermore, its metabolic stability suggests that it may not be rapidly degraded by enzymatic processes within the body, further enhancing its therapeutic potential.

The safety profile of this compound is another critical aspect being evaluated. Initial toxicological studies have shown that it exhibits low acute toxicity at tested doses, indicating a favorable safety margin for further development. However, comprehensive long-term studies are necessary to fully assess its safety profile before clinical trials can be initiated.

In conclusion, 4'-Methylsulfanyl-biphenyl-3-carboxylic Acid (CAS No. 728918-92-1) represents a promising candidate for pharmaceutical development due to its unique structural features and potential biological activities. Its biphenyl core combined with functional groups such as the methylsulfanyl and carboxylic acid moieties provides a versatile framework for designing novel therapeutic agents. Ongoing research aims to elucidate its mechanisms of action and optimize its pharmacokinetic properties to bring forth new treatments for various diseases.

• 825-99-0(3-(methylsulfanyl)benzoic acid)
• 1261964-62-8(3-Methyl-4-(4-methylthiophenyl)benzoic acid)
• 562836-64-0(4-(Methylthio)benzoic acid)
• 1261934-88-6(3-methyl-4-(4-methyl-2-thienyl)benzoic Acid)
• 1261993-47-8(2-(4-methyl-2-thienyl)benzoic Acid)
• 13205-48-6(4-(methylsulfanyl)benzoic acid)
• 4919-48-6(Benzoic acid,4,4'-thiobis-)
• 728918-90-9([1,1'-Biphenyl]-4-carboxylicacid, 4'-(methylthio)-)
• 885965-43-5(3'-(Methylthio)biphenyl-3-carboxylic acid)
• 252760-02-4(2-(4-Methylthiophenyl)benzoic acid)